AbbVie Inc. (NYSE:ABBV) went up by 3.75% from its latest closing price compared to the recent 1-year high of $175.91. The company’s stock price has collected 2.90% of gains in the last five trading sessions. The Wall Street Journal reported on 04/18/22 that J&J Settles With West Virginia in Opioid Suit for $99 Million
Is It Worth Investing in AbbVie Inc. (NYSE :ABBV) Right Now?
AbbVie Inc. (NYSE:ABBV) scored a price-to-earnings ratio above its average ratio, recording 20.58 x from its present earnings ratio. Plus, the 36-month beta value for ABBV is at 0.79. Opinions of the stock are interesting as 14 analysts out of 24 who provided ratings for AbbVie Inc. declared the stock was a “buy,” while 2 rated the stock as “overweight,” 6 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $165.20, which is $19.54 above the current price. ABBV currently public float of 1.77B and currently shorts hold a 0.72% ratio of that float. Today, the average trading volume of ABBV was 7.20M shares.
ABBV’s Market Performance
ABBV stocks went up by 2.90% for the week, with a monthly drop of -5.44% and a quarterly performance of -10.36%, while its annual performance rate touched 25.05%. The volatility ratio for the week stands at 2.53% while the volatility levels for the past 30 days are set at 2.34% for AbbVie Inc. The simple moving average for the period of the last 20 days is -1.53% for ABBV stocks with a simple moving average of 6.29% for the last 200 days.
Analysts’ Opinion of ABBV
Many brokerage firms have already submitted their reports for ABBV stocks, with SVB Leerink repeating the rating for ABBV by listing it as a “Underperform.” The predicted price for ABBV in the upcoming period, according to SVB Leerink is $140 based on the research report published on May 23rd of the current year 2022.
Daiwa Securities, on the other hand, stated in their research note that they expect to see ABBV reach a price target of $150. The rating they have provided for ABBV stocks is “Neutral” according to the report published on May 06th, 2022.
Morgan Stanley gave a rating of “Overweight” to ABBV, setting the target price at $192 in the report published on April 06th of the current year.
ABBV Trading at -5.75% from the 50-Day Moving Average
After a stumble in the market that brought ABBV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.44% of loss for the given period.
Volatility was left at 2.34%, however, over the last 30 days, the volatility rate increased by 2.53%, as shares sank -4.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.20% lower at present.
During the last 5 trading sessions, ABBV rose by +2.90%, which changed the moving average for the period of 200-days by +28.08% in comparison to the 20-day moving average, which settled at $145.33. In addition, AbbVie Inc. saw 5.96% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at ABBV starting from SEVERINO MICHAEL, who sale 79,801 shares at the price of $150.90 back on May 23. After this action, SEVERINO MICHAEL now owns 152,103 shares of AbbVie Inc., valued at $12,041,780 using the latest closing price.
SEVERINO MICHAEL, the Vice Chairman of AbbVie Inc., sale 100,000 shares at $154.04 during a trade that took place back on May 17, which means that SEVERINO MICHAEL is holding 152,103 shares at $15,404,400 based on the most recent closing price.
Stock Fundamentals for ABBV
Current profitability levels for the company are sitting at:
- +35.14 for the present operating margin
- +69.49 for the gross margin
The net margin for AbbVie Inc. stands at +20.41. Equity return is now at value 85.80, with 8.50 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 0.79.